Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Blood (2022) 140 (Supplement 1): 1794–1796.

https://doi.org/10.1182/blood-2022-156445

Published: 2022

Journal Articles

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Blood (2019) 134 (Supplement_1): 4202.

https://doi.org/10.1182/blood-2019-126164

Published: 2019

Journal Articles

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4326.

https://doi.org/10.1182/blood-2018-99-112109

Published: 2018

Journal Articles

The Impact of Interferon on Interferon-Related Genes in Polycythemia Vera and Allied Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4328.

https://doi.org/10.1182/blood-2018-99-110602

Published: 2018

Journal Articles

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Influences Deregulated Inflammation and Immune Genes in Polycythemia Vera and Allied Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 5490.

https://doi.org/10.1182/blood-2018-99-118690

Published: 2018

Journal Articles

Extracellular Matrix-Related Genes Are Deregulated in Peripheral Blood from Patients with Myelofibrosis and Related Neoplasms

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Caroline Riley, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 5491.

https://doi.org/10.1182/blood-2018-99-117122

Published: 2018

Journal Articles

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 580.

https://doi.org/10.1182/blood-2018-99-111255

Published: 2018

Journal Articles

Whole Blood Transcriptional Profiling Reveals Highly Deregulated Atherosclerosis Genes in Myeloproliferative Cancer

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Caroline Riley, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2018-99-117981

Published: 2018

Journal Articles

Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

Blood (2016) 128 (22): 627.

https://doi.org/10.1182/blood.V128.22.627.627

Published: 2016

Journal Articles

No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study

Lukas Frans Ocias, Dennis Lund Hansen, Thomas Kielsgaard Kristensen, Karin de Stricker, Daniel El Fassi, MD PhD, Jesper Stentoft, Jørn Starklint, Mikael Frederiksen, Marianne Tang Severinsen, Ole Weis Bjerrum, MD DMSc, Peter Møller, Torben Mourits-Andersen, MD, Ulrik Malthe Overgaard, Hans Carl Hasselbalch, MD Professor, DMSc, Klaus Bendtzen, Thomas Stauffer Larsen, MD PhD

Blood (2015) 126 (23): 5177.

https://doi.org/10.1182/blood.V126.23.5177.5177

Published: 2015

Journal Articles

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Henrik Hjorth-Hansen, MD PhD, Jesper Stentoft, Johan Richter, MD PhD, Perttu Koskenvesa, MD, Arta Dreimane, MD, Kimmo Porkka, MD PhD, Tobias Gedde-Dahl, MDPhD, Bjorn Gjertsen, MD PhD, Franz X. Gruber, MDPhD, Martin Hoglund, MD PhD, Anna Lubking, MD, Kristina Myhr-Eriksson, MD, Berit Markevärn, Hanne Vestergaard, MDPhD, Ole Weis Bjerrum, MDPhD, Leif Stenke, MDPhD, Satu Mustjoki, MD PhD, Ulla Stromberg, MDPhD

Blood (2015) 126 (23): 477.

https://doi.org/10.1182/blood.V126.23.477.477

Published: 2015

Journal Articles

The Impact of Interferon-alpha2 on HLA-Genes in Patients with Polycythemia Vera and Related Neoplasms

Vibe Skov, MSc, PhD, Caroline H Riley, Mads Thomassen, MSc, PhD, Lasse Kjær, MSc, PhD, Thomas Stauffer Larsen, MD PhD, Morten K Jensen, Ole Weis Bjerrum, MD DMSc, Torben A Kruse, Professor, PhD, Hans Carl Hasselbalch, MD Professor, DMSc

Blood (2015) 126 (23): 4097.

https://doi.org/10.1182/blood.V126.23.4097.4097

Published: 2015

Journal Articles

Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients

Mohamed El Missiry, MD MSc, Shady Adnan, MD MSc, Hanna Rajala, MD PhD, Ahmed Al-Samadi, DDS, PhD, Marja Ekblom, Berit Markevän, MD PhD, Ingbritt Åstrand-Grundström, Maren Wold, Birgitte Ravn Juhl, MD dr.MDsci, Ole Weis Bjerrum, MD DMSc, Inger Haulin, Kimmo Porkka, MD PhD, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen, MD PhD, Satu Mustjoki, MD PhD

Blood (2015) 126 (23): 4027.

https://doi.org/10.1182/blood.V126.23.4027.4027

Published: 2015

Journal Articles

Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study

Stine Ulrik Mikkelsen, MD, Lasse Kjær, MSc, PhD, Vibe Skov, MSc, PhD, Mads Emil Bjørn, MD PhDStudent, Christen Lykkegaard Andersen, MD PhD, Ole Weis Bjerrum, MD DMSc, Nana Brochmann, MD PhDStudent, Daniel El Fassi, MD PhD, Torben A Kruse, Professor, PhD, Thomas Stauffer Larsen, MD PhD, Torben Mourits-Andersen, MD, Claus Henrik Nielsen, MD Professor, DMSc, Niels Pallisgaard, MSc, Mads Thomassen, MSc, PhD, Hans Carl Hasselbalch, MD Professor, DMSc

Blood (2015) 126 (23): 824.

https://doi.org/10.1182/blood.V126.23.824.824

Published: 2015

Journal Articles

DNA Methylation Profiling of Sorted Cells from Myelofibrosis Patients reveals Aberrant Epigenetic Regulation of Immune Pathways and identifies Early MPN Driver Genes

Hans Carl Hasselbalch, MD PhD, Helene Myrtue Nielsen, Cand.scient, Fazila Asmar, MD, Christen Lykkegaard Andersen, MD, Lasse Sommer Kristensen, PhD, Kruse A Torben, Mads Thomassen, PhD, Thomas Stauffer Larsen, Vibe Skov, PhD, Caroline Riley, MD, Lise Lotte Hansen, PhD, Morten K. Jensen, MD, Ole Weis Bjerrum, MD, Vasu Punj, Kirsten Grønbæk, MD DMSc

Blood (2014) 124 (21): 4576.

https://doi.org/10.1182/blood.V124.21.4576.4576

Published: 2014

Journal Articles

Prediagnostic Thrombocytosis Increases the Risk of Advanced Gynecological Cancer and Increases Mortality Independently of Cancer Stage – a Population-Based Study

Christen Lykkegaard Andersen, MD, Volkert Siersma, MSc, Hans Carl Hasselbalch, MD PhD, Ole Weis Bjerrum, MD, Peter Felding, MD, Bent Lind, MD, Jan Palmblad, MD PhD, Niels de Fine Olivarius, MD

Blood (2014) 124 (21): 2791.

https://doi.org/10.1182/blood.V124.21.2791.2791

Published: 2014

Journal Articles

Human MICL Is An Early Marker In Myeloid Differentiation and Identifies a Subgroup Of CML Patients With Expanded Granulocyte-Macrophage Progenitor Populations At Diagnosis

Peter Buur van Kooten Niekerk, MD, Anne Stidsholt Roug, MD, PhD, Charlotte Christie Petersen, MSc PhD, Line Nederby, MSc, PhD, Charlotte Guldborg Nyvold, MSc, PhD, Ole Weis Bjerrum, MD, Andreja Dimitrijevic, MD, Marianne T. Severinsen, MD, PhD, Jesper Stentoft, MD, PhD, Peter Hokland, MD, DMSC

Blood (2013) 122 (21): 2704.

https://doi.org/10.1182/blood.V122.21.2704.2704

Published: 2013

Journal Articles

Risks of Eosinophil-Related End-Organ Damage, Hematological Malignancies and Death Are Significantly Increased Even below Consensus Threshold Criteria for Blood Eosinophilia

Christen Lykkegaard Andersen, MD, Volkert Siersma, MSc, Hanne Vestergaard, MD, Peter Felding, MD, Hans Carl Hasselbalch, MD, DMSc, Niels de Fine Olivarius, MD, Ole Weis Bjerrum, MD

Blood (2013) 122 (21): 2831.

https://doi.org/10.1182/blood.V122.21.2831.2831

Published: 2013

Journal Articles

JAK2 Exon 12 Mutant Allele Burden Study (JETMABS): A European Multicenter Study

Lasse Kjaer, Ph.D., Eric Lippert, Francois Girodon, MD, PhD, Susanne Schnittger, PhD, Serge Carillo, Caroline Riley, MD, Beatriz Bellosillo, Maj K. Westman, Ole Weis Bjerrum, MD, Marzena Wojtaszewska, Thomas Kristensen, MSc, PhD, Melanie Percy, PhD, Mary Frances McMullin, MD, MRCPath, Maruska Marusic, Caroline Rosmond, Lars Palmqvist, MD, PhD, Sylvie Hermouet, MD, Ph.D., Hans Carl Hasselbalch, MD, DMSc

Blood (2013) 122 (21): 4075.

https://doi.org/10.1182/blood.V122.21.4075.4075

Published: 2013

Journal Articles

A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia

Blood (2012) 120 (21): 803.

https://doi.org/10.1182/blood.V120.21.803.803

Published: 2012

NARROW

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

The Impact of Interferon on Interferon-Related Genes in Polycythemia Vera and Allied Neoplasms

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Influences Deregulated Inflammation and Immune Genes in Polycythemia Vera and Allied Neoplasms

Extracellular Matrix-Related Genes Are Deregulated in Peripheral Blood from Patients with Myelofibrosis and Related Neoplasms

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Whole Blood Transcriptional Profiling Reveals Highly Deregulated Atherosclerosis Genes in Myeloproliferative Cancer

Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

The Impact of Interferon-alpha2 on HLA-Genes in Patients with Polycythemia Vera and Related Neoplasms

Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients

Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study

DNA Methylation Profiling of Sorted Cells from Myelofibrosis Patients reveals Aberrant Epigenetic Regulation of Immune Pathways and identifies Early MPN Driver Genes

Prediagnostic Thrombocytosis Increases the Risk of Advanced Gynecological Cancer and Increases Mortality Independently of Cancer Stage – a Population-Based Study

Human MICL Is An Early Marker In Myeloid Differentiation and Identifies a Subgroup Of CML Patients With Expanded Granulocyte-Macrophage Progenitor Populations At Diagnosis

Risks of Eosinophil-Related End-Organ Damage, Hematological Malignancies and Death Are Significantly Increased Even below Consensus Threshold Criteria for Blood Eosinophilia

JAK2 Exon 12 Mutant Allele Burden Study (JETMABS): A European Multicenter Study

A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only